ClinicalTrials.gg
RecruitingNCT05855031Updated May 17, 2023

The Liver Care Trial

An interventional study of Transient Elastography in Alcoholic Liver Disease, Alcohol Use Disorder and Alcohol Abuse, sponsored by Zealand University Hospital. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Zealand University Hospital · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units/week) throughout the last months, and assessed 6 months after randomization.

02

Conditions studied

  • Alcoholic Liver Disease
  • Alcohol Use Disorder
  • Alcohol Abuse
  • Alcoholism
  • Fibrosis, Liver
  • Alcohol-Related Disorders

Keywords

  • Screening
  • Fibroscan
  • Liver stiffness measurement
  • abstinence
03

In context

Liver Diseases, Alcoholic

74 studies on the registry are indexed under Liver Diseases, Alcoholic; 25 are open to participants now.

This study's planned enrollment of 408 is above the median of 90 across 44 interventional studies indexed under Liver Diseases, Alcoholic.

Browse Liver Diseases, Alcoholic studies →

Lead sponsor

Zealand University Hospital is the lead sponsor of 237 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Attending outpatient treatment for alcohol use disorder (international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use) at Novavi Køge or Novavi Roskilde
  • Informed written consent

Exclusion criteria

Exclusion Criteria:

  • Not speaking Danish or English
  • Severe liver disease (known by the participant)
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
408 participants (estimated)

Study arms

  • Experimental
    Intervention

    An invitation to a liver stiffness measurement (Transient Elastography), to blood sampling and a leaflet on alcohol-related disease.

    Diagnostic Test: Transient Elastography

  • No intervention
    Control

    An invitation to screening by blood sampling with Fib-4

Interventions

  • Diagnostic testTransient Elastography

    One transient elastography 1-2 weeks after randomization

    Also known as: Fibroscan, Liver stiffness measurement

06

What researchers measure

Primary outcomes

  1. Alcohol abstinence or light consumption (≤ 10 units/week) the last 30 days (yes/no) assessed 6 months since randomization

    Assessed By telephone interview or health record

    Time frame: Assessed 6 months after randomization

Secondary outcomes

  1. Heavy drinking days last 30 days

    Assessed by telephone interview or health record

    Time frame: Assessed 6 months after since randomization

  2. Change in AUDIT-C score (yes or no) since randomization

    AUDIT: the Alcohol Use Disorders Identification Test is a validated manual for use in primary care to identify persons with hazardous and harmful patterns of alcohol consumption

    Time frame: 6 months after randomization

Other outcomes

  1. Improvement or no decrease in motivation to cut down on alcohol (yes or no)

    Assessed by telephone interview via questionnaire

    Time frame: 6 months after randomization

  2. Improvement or no decrease in physical and mental health-related quality of life (SF-12) (yes or no), calculated as the difference between baseline and follow-up.

    SF 12 (12-Item Short Form Survey) is a validated self-reported outcome measure assessing the impact of health on an individual's everyday life

    Time frame: Assessed 6 months after randomization

  3. Comparing abstinence or light consumption last 30 days between those in the intervention group with a screen negative result with those in the control group.

    Light consumption \< 10 units/week

    Time frame: Assessed 6 months after randomization

  4. Comparing alcohol consumption amount between those with a positive fibroscan vs. those with a negative fibroscan

    Time frame: Assessed 6 months after randomization

  5. Improvement or no decrease in smoking (yes/no)

    By logistic regression

    Time frame: Assessed 6 months after randomization

07

Study locations

2 of 2 sites recruiting
  • Novavi Køge
    Køge, 4600, Denmark
    Recruiting
  • Novavi Roskilde
    Roskilde, 4000, Denmark
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Nov 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2023
First posted
May 11, 2023
StartActual
May 8, 2023
Primary completionEst.
Nov 1, 2026
CompletionEst.
May 1, 2027
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05855031
Collaborators
Novavi, Aarhus University Hospital, Frederiksberg University Hospital, University of Copenhagen
Responsible party
Sponsor
First posted
May 11, 2023
Start date
May 8, 2023
Primary completion
Nov 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
May 17, 2023

Study contacts

Pernille Dahlin, MD
Contact
pedah@regionsjaelland.dk
+45 30291114
Gro Askgaard, PHD
Contact
gras@regionsjaelland.dk
Gro Askgaard, PHD
principal investigator · Zealand University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion